Cefixime
 |
|
|---|---|
| Systematic (IUPAC) name | |
| (6R,7R)-7-{[2-(2-amino-1,3-thiazol-4-yl)-2-(carboxy methoxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia- 1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
|
| Clinical data | |
| Trade names | Suprax |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a690007 |
| Pregnancy cat. | B |
| Legal status | ℞ Prescription only |
| Routes | Oral |
| Pharmacokinetic data | |
| Bioavailability | 40% to 50% |
| Protein binding | Approximately 60% |
| Half-life | Variable Average 3 to 4 hours |
| Excretion | Renal and biliary |
| Identifiers | |
| CAS number | 79350-37-1  |
| ATC code | J01DD08 |
| PubChem | CID 5362065 |
| DrugBank | APRD00583 |
| ChemSpider | 4514923 |
| UNII | 97I1C92E55 |
| KEGG | D00258 |
| ChEBI | CHEBI:472657 |
| ChEMBL | CHEMBL1541 |
| Chemical data | |
| Formula | C16H15N5O7S2 |
| Mol. mass | 453.452 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
|
Cefixime is an oral third generation cephalosporin antibiotic. Cefixime is a cephalosporin antibiotic used to treat infections caused by bacteria. These include infections of the: Ear (otitis media caused by Haemophilus influenzae, Moraxella catarrhalis,and S. pyogenes.) Nose, sinuses (sinusitis), Throat (tonsillitis, pharyngitis caused by S. pyogenes ), Chest and lungs (bronchitis, pneumonia caused by Streptococcus pneumoniae and Haemophilus influenzae) and Urinary system and Uncomplicated gonorrhea caused by Neisseria gonorrhoeae.
The bactericidal action of cephalosporin due to the inhibition of cell wall synthesis.
It is always better to perform appropriate cultures and susceptibility studies to determine the causative organism and its sensitivity to cefixime.
Cefixime is contraindicated in patients with known sensitivity or allergies to cephalosporin class of antibiotics.
Adverse Drug Reactions include diarrhea, dyspepsia, nausea, vomitting. Hypersensitivity reactions like skin rashes, utricaria, Stevens-Johnson syndrome have been reported. There is no specific antidote for cefixime overdosage. Gastric lavage may performed. Dialysis will not remove cefixime in significant quantities.
It was sold under the trade name Suprax in the USA until 2003 when it was taken off the market by drug manufacturer Wyeth after its patent expired. The oral suspension form of "Suprax" was re-launched by Lupin in the USA.
Cefixime API is manufactured by many pharmaceutical companies the world over. The major manufacturers are based in India.
[edit] References
http://www.nlm.nih.gov/medlineplus/druginfo/meds/a690007.html
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
